Alnylam Pharmaceuticals | ALNY - Interest Income


Alnylam Pharmaceuticals reported $26.63M in Interest Income for its fiscal quarter ending in December of 2025.





Interest Income Change Date
Acadia Pharmaceuticals USD 8.33M 86K Dec/2025
Agios Pharmaceuticals USD 12.41M 959K Dec/2025
Alnylam Pharmaceuticals USD 26.63M 2.05M Dec/2025
Arrowhead Research USD 9.69M 637K Dec/2025
BioCryst Pharmaceuticals USD -0.13 3.59M Dec/2024
BioMarin Pharmaceutical USD 22.56M 3.35M Mar/2026
Incyte USD 33.69M 2.93M Mar/2026
Ionis Pharmaceuticals USD -0.66 0.29 Dec/2024
Moderna USD 70M 3M Dec/2025
Regeneron Pharmaceuticals USD 193.3M 18.2M Dec/2025
Sanofi EUR 114M 38M Sep/2025
Sarepta Therapeutics USD 8.74M 359K Dec/2025
Takeda JPY 87.87B 43.48B Dec/2025
Tectonic Therapeutic USD 1.74M 217K Dec/2024
Ultragenyx Pharmaceutical USD 6.51M 649K Dec/2025
Vertex Pharmaceuticals USD 114.8M 7.1M Mar/2026
Xencor USD 6.2M 338K Dec/2025